{
  "casebody": {
    "data": "<?xml version='1.0' encoding='utf-8'?>\n<casebody firstpage=\"878\" lastpage=\"885\" xmlns=\"http://nrs.harvard.edu/urn-3:HLS.Libr.US_Case_Law.Schema.Case_Body:v1\">\n<parties data-order=\"0\" data-type=\"parties\" id=\"b936-5\">Patrick R. DRISCOLL, Appellant, v. Tony CEBALO and Robert A. Walde, Appellees, v. Karl HOEGERLE, Hans Cellarius, Paul Rathgeb, and Jurg Rumpf, Appellees. Tony CEBALO and Robert A. Walde, Appellants, v. Patrick R. DRISCOLL, Appellee, v. Carl METZGER, Ludwig Eue, and Helmuth Hack, Appellees.</parties>\n<docketnumber data-order=\"1\" data-type=\"docketnumber\" id=\"b936-15\">Appeal Nos. 83-968, 83-654.</docketnumber>\n<docketnumber data-order=\"2\" data-type=\"docketnumber\" id=\"Am0\">Interference Nos. 97757, 98208.</docketnumber>\n<court data-order=\"3\" data-type=\"court\" id=\"b936-17\">United States Court of Appeals, Federal Circuit.</court>\n<decisiondate data-order=\"4\" data-type=\"decisiondate\" id=\"b936-18\">April 6, 1984.</decisiondate>\n<attorneys data-order=\"5\" data-type=\"attorneys\" id=\"b937-7\"><page-number citation-index=\"1\" label=\"879\">*879</page-number>Donald A. Peterson, Chicago, Ill., argued for appellants. With him on brief were Kenneth R. Adamo and Herbert D. Hart, III, Chicago, Ill.; Leroy Whitaker, Indianapolis, Ind., of counsel.</attorneys>\n<attorneys data-order=\"6\" data-type=\"attorneys\" id=\"b937-9\">Peter G. Dilworth, Garden City, N.Y., argued for appellee Driscoll. With him on brief were Stephen D. Murphy and Rocco S. B\u00e1rrese, Garden City, N.Y.</attorneys>\n<p data-order=\"7\" data-type=\"judges\" id=\"b937-10\">Before DAVIS, Circuit Judge, NICHOLS,<footnotemark>*</footnotemark> Senior Circuit Judge, and MILLER, Circuit Judge.</p>\n<footnote data-order=\"8\" data-type=\"footnote\" id=\"x999-1\" label=\"*\">\n<p id=\"b937-13\"> Judge Nichols assumed senior status effective October 1, 1983.</p>\n</footnote>\n<opinion data-order=\"9\" data-type=\"opinion\" id=\"x999-2\" type=\"majority\">\n<author id=\"b937-11\">JACK R. MILLER, Circuit Judge.</author>\n<p id=\"b937-12\">These consolidated appeals under 35 U.S.C. \u00a7 141 (1976) arose out of two interferences in which the Patent and Trademark Office Board of Patent Interferences (\u201cboard\u201d) awarded priority to Patrick R. Driscoll (\u201cDriscoll\u201d) in Interference No. 98,-208 (one phantom count) and to Tony C\u00e9ba-lo and Robert A. Walde (\u201cC\u00e9balo\u201d) in Interference No. 97,757 (two counts). Both C\u00e9-balo and Driscoll appeal from the awards of priority in the respective interferences; Driscoll also appeals from the board\u2019s dismissal of the fraud issue (belatedly raised in his brief below) in Interference No. 98,-208.</p>\n<p id=\"b937-17\">The dispositive issue is whether the party C\u00e9balo violated his duty of disclosure owed the Patent and Trademark Office (\u201cPTO\u201d) during prosecution of his series of applications involved in both interferences. Because, as we hold, C\u00e9balo violated his duty, the board\u2019s decision in favor of C\u00e9balo in Interference No. 97,757 must be reversed, and its decision in Interference No. 98,208 in favor of Driscoll must be affirmed.</p>\n<p id=\"b937-18\">\n<em>Interference No. 97,757</em>\n</p>\n<p id=\"b937-19\">The party Driscoll filed his patent application, Serial No. 113,679, on February 8, 1971, and was accorded the benefit of his earlier applications, Serial No. 702,189, filed February 1, 1968 (as to Count 1 only), Serial No. 782,756, filed December 10,1968, and Serial No. 818,078, filed April 21, 1969, under 35 U.S.C. \u00a7 120. The junior party C\u00e9balo filed two continuation-in-part applications (Serial Nos. 762,604, September 25, 1968, and 856,461, September 9, 1969) and was accorded the benefit of his earlier parent application, Serial No. 712,585, filed March 13, 1968, under 35 U.S.C. \u00a7 120.<footnotemark>1</footnotemark></p>\n<p id=\"b937-20\">The subject matter of Interference No. 97,757 involves certain thiadiazole urea compounds having utility as herbicides. The two counts of the interference are directed to fluorinated organic compounds as follows:</p>\n<blockquote id=\"b937-21\">1. A compound as defined in claim 1,[<footnotemark>2</footnotemark>] which is N-[5-trifluoromethyl-l,3,4-thiadiazolyl (2) ]-N\u2019-methyl urea.</blockquote>\n<blockquote id=\"A3V\"><page-number citation-index=\"1\" label=\"880\">*880</page-number>2. A compound as defined in claim 1, which is N-[5-trifluoromethyl-l,3,4-thia-diazolyl (2) ]-N, N\u2019-dimethyl urea.</blockquote>\n<p id=\"Ac1\">Driscoll filed a motion to strike the C\u00e9ba-lo application and to deny C\u00e9balo the benefit of his earlier-filed application for violation of 37 C.F.R. \u00a7 1.56 \u2014 specifically for fraud in withholding a prior art reference. Treating Driscoll\u2019s motion as a petition to strike pursuant to said rule, the Commissioner of Patents and Trademarks deferred action on the motion, on related oppositions, and on certain declarations, pending final decision by the board on the question of priority and all ancillary issues. The fraud issue was deemed by the board to be ancillary to priority and was briefed.</p>\n<p id=\"A-U\">Claim 1 of Cebalo\u2019s parent application reads as follows:</p>\n<blockquote id=\"aba-dedup-1\">Thiadiazolines having the structure</blockquote>\n<blockquote id=\"pAbf\">\n<img class=\"blockquote\" height=\"252\" src=\"data:image/png;base64,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\" width=\"457\"/>\n</blockquote>\n<blockquote id=\"AWqU\">and tautomers thereof:</blockquote>\n<blockquote id=\"ake-dedup-1\">wherein A is a substituent selected from the group consisting of C1-C7 acyclic hydrocarbon radicals and halogenated derivatives of said radicals, wherein each halogen is independently selected from the group consisting of F, Cl and Br; and B is a substituent selected from the group consisting of lower acyclic hydrocarbon radicals, phenyl, monosubstituted phenyl and poly-substituted phenyl wherein each substituent is independently selected from the group consisting of:</blockquote>\n<blockquote id=\"a2y-dedup-0\">(a) Cl</blockquote>\n<blockquote id=\"Ay2a\">(b) Br</blockquote>\n<blockquote id=\"AOt\">(c) -N02</blockquote>\n<blockquote id=\"adr-dedup-0\">(d) -CF3</blockquote>\n<blockquote id=\"Amse\">(e) a lower alkyl radical</blockquote>\n<blockquote id=\"asx-dedup-1\">(f) a lower alkoxy radical, and</blockquote>\n<blockquote id=\"ao9-dedup-0\">(g) the group:</blockquote>\n<blockquote id=\"pAOVo\">\n<img class=\"blockquote\" height=\"196\" src=\"data:image/png;base64,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\" width=\"303\"/>\n</blockquote>\n<blockquote id=\"avi-dedup-0\">wherein each D represents an independently selected lower alkyl radical.</blockquote>\n<p id=\"azx-dedup-1\">Thus, claim 1, as originally filed, encompasses compounds in which the 5-position of the heterocyclic ring is substituted with either a nonfluorinated <em>alkyl group </em>(which includes a lower alkyl group) or a fluorinat-ed alkyl group. The compounds encompassed by claim 1 and having a fluorinated alkyl group serve as key starting materials for the compounds of the counts of Interference No. 97,757, and the compounds having a nonfluorinated alkyl group serve as key starting materials for compounds of the single phantom count of Interference No. 98,208.</p>\n<p id=\"AmHX\">In the \u201cPrior Art\u201d section of the application, C\u00e9balo disclosed two references: J. Pharm. Soc. Japan 74, 1044-8 (1954), which discloses \u201csomewhat related compounds\u201d such as l-(5-methyl-l,3,4-thiadiazol-2-yl)-3-phenylurea, and an article in Farmaco Ed. Sci. 22(6), 393-401 (1967), which \u201cdiscloses the use of l-(5-alkyl-l,3,4-thiadiazol-2-yl)ureas as intermediates for the production of isomeric l,3-bis-(5-alkyl-l,3,4-thiadia-zol-2-yl)ureas.\u201d</p>\n<p id=\"Aq4v\">C\u00e9balo did <em>not </em>cite Canadian Patent No. 745,623, issued November 1, 1966 (\u201cCanadian patent\u201d), which discloses \u201cagents for combating pests especially weeds and phy-topathogenic microorganisms\u201d containing a compound of the general formula:</p>\n<blockquote id=\"b939-4\">\n<page-number citation-index=\"1\" label=\"881\">*881</page-number>\n<img class=\"blockquote\" height=\"274\" src=\"data:image/png;base64,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\" width=\"619\"/>\n</blockquote>\n<blockquote id=\"b939-5\">or of the isomeric formula</blockquote>\n<blockquote id=\"b939-6\">\n<img class=\"blockquote\" height=\"298\" src=\"data:image/png;base64,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\" width=\"626\"/>\n</blockquote>\n<blockquote id=\"b939-7\">where is a phenyl radical which may be substituted by a lower alkyl radical or by the group -CF3, or a saturated or unsaturated, preferably lower, aliphatic radical; R2 represents a hydrogen atom or a lower alkyl radical, or a phenyl radical which may be substituted by at least one, preferably lower, alkyl or alkoxy group, at least one halogen atom (preferably a chlorine, bromine or fluorine atom), or by at</blockquote>\n<blockquote id=\"b939-8\">A least one -N02, -CF3. or , group (in &gt;A\u2019</blockquote>\n<blockquote id=\"b939-11\">which A and A\u2019 each represents a hydrogen atom or a lower alkyl radical); and R3 stands for a hydrogen atom or a preferably lower alkyl radical or for the radical R-CO- (where R is a preferably lower alkyl radical), or a salt or quaternary ammonium compound thereof</blockquote>\n<p id=\"b939-12\">It is clear that the Canadian patent discloses compounds in which the 5-position of the ring is substituted with, <em>inter alia, </em>a non-fluorinated lower alkyl group.</p>\n<p id=\"b939-13\">An employee with the Patent Department of Cebalo\u2019s assignee prepared a 15-page \u201cArt Search\u201d report, dated August 3, 1967, which stated that \u201c[t]he principal references are to Ciba\u2019s Canadian [i.e., the Canadian patent] and Belgian 2,5-substitut-ed thiadiazole patents ____\u201d The report discussed the relevance of the Canadian patent as well as the fact that it specifically sets forth the following compound, in which the 5-position is substituted with a nonfluorinated methyl group:</p>\n<blockquote id=\"b939-16\">\n<img class=\"blockquote\" height=\"192\" src=\"data:image/png;base64,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\" width=\"684\"/>\n</blockquote>\n<blockquote id=\"b939-17\">[Example 2(a) of the Canadian patent]</blockquote>\n<p id=\"b939-18\">After some input from the inventors, Ceba-lo\u2019s attorney prepared a draft application, including claim 1, encompassing compounds having either a fluorinated or non-fluorinated alkyl group in the 5-position of the heterocyclic ring, and forwarded it to Doctor C\u00e9balo for review on February 12, 1968. Doctor C\u00e9balo returned the draft application to the attorney about ten days later with the following note on Claim 1:</p>\n<blockquote id=\"AMK6\">Note [blur] A good deal of what we claim here is claimed in the attached sheets from Canadian Patent 745,623.</blockquote>\n<p id=\"b939-19\">Doctor C\u00e9balo later testified that he then realized that \u201ca good deal of the compounds\u201d disclosed by the reference could not be tautomerized, as he at first had believed, and, \u201c[t]herefore, I came to the conclusion that the patent was inoperable, and, therefore, I concluded that it was not a valid reference and it need not be considered.\u201d Doctor Cebalo\u2019s co-inventor (Walde) testified to the same effect. However, Doctor C\u00e9balo admitted under cross-examination that Example 2(a) (the compound shown above) of the Canadian patent was included within the scope of claim 1 of the parent C\u00e9balo application. Claim 1 was not substantially changed by the C\u00e9balo attorney before filing and was carried forward into Cebalo\u2019s two subsequent continuation-in-part applications. The parent and the first continuation-in-part application were permitted to become abandoned in response to requirements for restriction with no prosecution on the merits. During prosecution of the second continuation-in-part (the application involved in the interference below and containing claim 1), the claims were rejected for double patenting, reciting duplicates, and failing to define the invention with the definiteness required by 35 U.S.C. \u00a7 112.</p>\n<p id=\"b939-20\">At this point, a new attorney was assigned to handle the C\u00e9balo application and, after an interview with the examiner, <page-number citation-index=\"1\" label=\"882\">*882</page-number>claim 1 was cancelled. By an amendment of April 6, 1970, claim 41, setting forth a narrower group of compounds, all of which serve as starting materials for the compounds of the counts and in which the 5-position can only be substituted with a fluorinated alkyl group, was substituted for claim 1:</p>\n<blockquote id=\"b940-4\">41. Thiadiazoles having the structure:</blockquote>\n<blockquote id=\"b940-5\">\n<img class=\"blockquote\" height=\"282\" src=\"data:image/png;base64,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\" width=\"479\"/>\n</blockquote>\n<blockquote id=\"b940-6\">wherein A is a Ci~C7 haloalkyl radical, wherein each halogen is independently selected from the group consisting of F, Cl, and Br; and B is selected from the group consisting of lower alkyl and lower alkenyl radicals.</blockquote>\n<p id=\"b940-7\">The Canadian patent was, again, <em>not </em>cited to the PTO in the amendment of April 6, 1970, notwithstanding that some of the compounds of claim 41 differ by as little as one fluorine atom from compounds disclosed by the Canadian patent and that some of the latter are herbicidal analogs of some of the former. <em>See In re Albrecht, </em>579 F.2d 92, 94, 198 USPQ 208, 209 (C.C.P. A. 1978); <em>In re Widmer, </em>353 F.2d 752, 757, 53 C.C.P.A. 762, 147 USPQ 518, 523 (1965). Prosecution of claim 41 on the merits ended when this interference was declared.</p>\n<p id=\"b940-8\">In response to Driscoll\u2019s motion to strike the C\u00e9balo application for fraud and to deny C\u00e9balo the benefit of his earlier-filed parent application, C\u00e9balo submitted a declaration of his new attorney stating that, in a memorandum summarizing a conference with Doctor C\u00e9balo, he had referred to the fact that the generic structure of the thia-diazoles set forth in claim 1 \u201ccould possibly conflict with known prior art\u201d; that he had added to the memorandum the further notation: \u201cTony [C\u00e9balo] to send art. Possibly cancel Cls. 1-7 not patentable\u201d; that he filed an amendment canceling claim 1 and substituting therefor claim 41 which defined the substituents \u201cA\u201d and \u201cB\u201d in narrow terms; and that so amending the claim \u201cclearly avoided and still avoids any possible conflict with all known and material prior art, including inter alia the Canadian patent.\u201d Doctor C\u00e9balo testified that he thought that the claim was amended to exclude everything that was in the Canadian patent and that the purpose of the amendment was that \u201cthere wouldn\u2019t be any possibility of having any overlap or infringing on the prior art.\u201d</p>\n<p id=\"b940-10\">In its opinion of September 21, 1982, the board concluded that the Canadian patent would have been material to claim 1; that \u201cany reasonable examiner would have rejected the Claim as being unpatentable over The Reference\u201d; and that there was gross negligence, \u201cif not specific intent to deceive,\u201d in carrying out Cebalo\u2019s duty of disclosure to the PTO. However, the board found that there was no reliance by the PTO because neither claim 1, nor substitute claim 41, had been allowed by the PTO. C\u00e9balo was awarded priority on both counts.</p>\n<p id=\"b940-11\">Following the board\u2019s decision, Driscoll renewed his motion to strike Cebalo\u2019s patent application under 37 C.F.R. \u00a7 1.56, maintaining that the board\u2019s findings of materiality and gross negligence were sufficient for a holding that C\u00e9balo committed attempted fraud or inequitable conduct proscribed by 37 C.F.R. \u00a7 1.56. C\u00e9balo filed an opposition, and the board forwarded the motion to the Commissioner of Patents and Trademarks for his consideration. The renewed motion was denied by the Deputy Commissioner with the following discussion:</p>\n<blockquote id=\"b940-12\">Since former Deputy Commissioner Parker entered the decision (Paper No. 153) denying Driscoll's first motion to strike without prejudice to renewal, the provisions of 37 CFR \u00a7 1.56 have been amended. Under current practice, if the inequitable conduct set forth in 37 CFR \u00a7 1.56(d) is determined to have occurred, the examiner enters a rejection. Patent applications are no longer stricken for fraud.</blockquote>\n<p id=\"b941-4\"><page-number citation-index=\"1\" label=\"883\">*883</page-number>Driscoll filed a request for reconsideration of the Deputy Commissioner\u2019s order and C\u00e9balo opposed. The Deputy Commissioner, on reconsideration, denied Driscoll\u2019s renewed petition to strike, but did so without prejudice to renewal after a final decision was entered in the interference. The Deputy Commissioner withdrew from his former position that the Commissioner no longer had authority to strike applications, but stated:</p>\n<blockquote id=\"b941-5\">Fraud issues are ancillary to priority and are resolved by the Board along with other issues in determining priority. In the recent past, it has been the practice of the PTO to defer rulings on petitions to strike until the Board rules on any fraud issues at final hearing. It is implicit from former Deputy Commissioner Parker\u2019s decision that such a ruling should be made by the Commissioner \u2014 if it is to be made at all \u2014 only after a decision in the interference is final (either because no appeal is filed or, if an appeal is filed, when the decision on appeal becomes final).</blockquote>\n<p id=\"b941-6\">It was also the Deputy Commissioner\u2019s position that, once a decision in the interference becomes final, \u201cthe Commissioner may then decide what further action \u2014 if any \u2014 might be taken under applicable PTO rules <em>consistent with the final decision in the interference, </em>whether entered by the Board or a reviewing court.\u201d (Emphasis in original.)</p>\n<p id=\"b941-7\">\n<em>Interference No. 98,208</em>\n</p>\n<p id=\"a0r-dedup-0\">C\u00e9balo filed his patent application, Serial No. 178,379 on September 7, 1971, and again was awarded the benefit of his earlier application Serial No. 712,585 (including the above-discussed Claim 1) filed March 13, 1968.</p>\n<p id=\"b941-8\">Driscoll was involved in this interference on the basis of the same application (Serial No. 113,679, filed February 8, 1971) as in Interference No. 79,757 and was accorded the benefit of the same earlier-filed applications (Serial Nos. 818,078 filed April 21, 1969, and 702,189 filed February 1, 1968) under 35 U.S.C. \u00a7 120.<footnotemark>3</footnotemark></p>\n<p id=\"b941-10\">The subject matter of this interference is also a class of compounds having utility as herbicides. However, unlike the counts in Interference No. 79,757, the single phantom count in Interference No. 98,208 encompasses only wowfluorinated compounds, as follows:</p>\n<blockquote id=\"b941-11\">A compound of the formula</blockquote>\n<blockquote id=\"AqL8\">\n<img class=\"blockquote\" height=\"271\" src=\"data:image/png;base64,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\" width=\"618\"/>\n</blockquote>\n<blockquote id=\"b941-14\">wherein X = oxygen or sulfur,</blockquote>\n<blockquote id=\"b941-15\">R = alkyl,</blockquote>\n<blockquote id=\"b941-16\">Rx = alkyl, and</blockquote>\n<blockquote id=\"Ajd\">Rg = alkyl or hydrogen.</blockquote>\n<p id=\"b941-17\">As related earlier, Driscoll belatedly raised the issue of fraud (by C\u00e9balo in failing to bring the Canadian patent to the attention of the PTO) in his brief before the board, not having previously submitted a motion to dissolve under 37 C.F.R. \u00a7 1.231. The board found that the facts regarding the Canadian patent were not known by Driscoll until after the discovery period. Driscoll then filed a motion to strike pursuant to 37 C.F.R. \u00a7 1.56, which, the board said, could have been treated as \u201ctantamount to a timely \u00a7 1.231 motion\u201d (as was the motion to strike in Interference No. 97,757), except for the fact that the motion to strike was directed to conduct by C\u00e9balo other than the withholding of the Canadian patent. The board held that Driscoll was not, for the first time at final hearing, entitled to raise matters not included in his motion to strike, because there was no adequate showing why the issue could not have been earlier raised.</p>\n<p id=\"b942-3\"><page-number citation-index=\"1\" label=\"884\">*884</page-number>The board recognized its discretion to consider the fraud issue \u201cto prevent manifest injustice,\u201d but declined to do so for the following reason:</p>\n<blockquote id=\"b942-4\">We have already decided in the other interference, on the precise facts presented, that fraud did not lie against C\u00e9balo.</blockquote>\n<p id=\"b942-5\">ANALYSIS</p>\n<p id=\"b942-6\">\u201cEstablishing that a patent was procured by fraud or with such egregious conduct as to render it unenforceable requires clear, unequivocal, and convincing evidence of an intentional misrepresentation or withholding of a material fact from the PTO.\u201d <em>Orthopedic Equipment Co. v. All Orthopedic Appliances, Inc., </em>707 F.2d 1376, 1383, 217 USPQ 1281, 1286 (Fed.Cir.1983); <em>Square Liner 360\u00b0, Inc. v. Chisum, </em>691 F.2d 362, 374, 216 USPQ 666, 674-75 (8th Cir.1982). Where, as in this case, a patent has not been issued, the same standard of proof applies with respect to the proceedings before the PTO. <em>Norton v. Curtiss, </em>433 F.2d 779, 797, 57 C.C.P.A. 1384, 167 USPQ 532, 547-48 (1970).</p>\n<p id=\"b942-7\">We agree with the board\u2019s conclusion in Interference No. 97,757 that the Canadian patent would have been material to claim 1 of the C\u00e9balo application. Example 2(a) of that patent is clearly within the scope of claim 1. That claim 1 was canceled and claim 41 substituted for it did not, contrary to the declaration of Cebalo\u2019s attorney, render the Canadian patent immaterial to claim 41. As pointed out above, some of the compounds of the Canadian patent are herbicidal analogs of some of the compounds within claim 41. Thus, claim 41 would have been prima facie obvious from the Canadian patent. Accordingly, we hold that Cebalo\u2019s attempt to excuse his failure to disclose the Canadian patent during prosecution of his parent application by substituting claim 41 for claim 1, without bringing his failure to disclose to the attention of the PTO, must fail. <em>See Rohm &amp; Haas Co. v. Crystal Chemical Co., </em>722 F.2d 1556, 1559, 1571-72, 220 USPQ 289, 291-92, 301-02 (Fed. Cir.1983) (holding that intentional misstatements during a \u201cwhole sequence of copending applications\u201d were not \u201ccured\u201d by the kind of disclosure made to the PTO before claims were allowed). That the counts of either interference may be patentable over the withheld prior art, as argued by C\u00e9balo, is not relevant. What is relevant is that the board found that a reasonable examiner would have considered such prior art important in deciding whether to allow the parent application. 37 C.F.R. \u00a7 1.56(d) (1982).<footnotemark>4</footnotemark> <em>See American Hoist &amp; Derrick Co. v. Sowa &amp; Sons, Inc., </em>725 F.2d 1350, 1362, 220 USPQ 763, 773 (Fed.Cir.1984).</p>\n<p id=\"b942-12\">In Interference No. 97,757, the board said:</p>\n<blockquote id=\"b942-13\">Accordingly, reprehensible as Cebalo\u2019s conduct may have been, and we consider it to be quite reprehensible, we are constrained to find no fraud because there was no reliance by the Examiner upon Cebalo\u2019s violation of his duty to disclose.</blockquote>\n<p id=\"A8MY\">This was error. <em>See Rohm &amp; Haas Co. v. Crystal Chemical Co., supra. </em>Although the previously quoted regulation 1.56(d) was not in effect at the time claim 41 was substituted for claim 1 (April, 1970), we conclude that the regulation essentially represents a codification of the \u201cclean hands\u201d maxim as applied to patent applicants. <em>True Temper Corp. v. CF &amp; I Steel Corp., </em>601 F.2d 495, 504 n. 9, 202 USPQ 412, 419 n. 9 (10th Cir.1979). <em>See Keystone Driller Co. v. General Excavator Co., </em>290 <page-number citation-index=\"1\" label=\"885\">*885</page-number>U.S. 240, 246-47, 54 S.Ct. 146, 148, 78 L.Ed. 293 (1933); cited, <em>inter alia, </em>in <em>Walker Process v. Food Machinery, </em>382 U.S. 172, 176, 86 S.Ct. 347, 350, 15 L.Ed.2d 247 (1965), <em>Precision Co. v. Automotive Co., </em>324 U.S. 806, 819, 65 S.Ct. 993, 999, 89 L.Ed. 1381 (1945), <em>Monsanto Co. v. Rohm &amp; Haas Co., </em>456 F.2d 592, 595, 172 USPQ 323, 325 (3d Cir.1972), <em>Kearney &amp; Trecker Corp. v. Giddings &amp; Lewis, Inc., </em>452 F.2d 579, 594, 171 USPQ 650, 662 (7th Cir.1971), and <em>Norton v. Curtiss, supra </em>433 F.2d at 792 n. 12; Miller, <em>Fraud on the PTO, </em>58 J.PAT.OFF.SOC\u2019Y 271, 284 (1976). We note that the <em>Official Gazette </em>of the PTO (Vol. 955, No. 4, Feb. 22, 1977) states that regulation 1.56 \u201ccodifies the existing Office policy on fraud and inequitable conduct, which is believed consistent with the prevailing case law in the federal courts.\u201d</p>\n<p id=\"APl9\">Significantly, the board found that:</p>\n<blockquote id=\"A6K\">the totality of the circumstances surrounding the actions of C\u00e9balo, in particular, counsel for C\u00e9balo, evidence, if not specific intent to deceive, such a pattern of misrepresentation in the two applications as to amount to gross negligence in carrying out the duty of disclosure owed the PTO.</blockquote>\n<p id=\"b943-5\">We are satisfied that the board\u2019s finding of gross negligence \u2014 in the sense of neglect of duty \u2014 is sufficiently supported by the evidence. The correspondence between the C\u00e9balo attorneys and the inventors demonstrates full awareness of the materiality of the Canadian patent notwithstanding any temporary subjective belief of inoperability on the part of the inventors. Where they knew, or should have known, that the withheld reference would be material to the PTO\u2019s consideration, their failure to disclose the reference is sufficient proof of the existence of an intent to mislead the PTO. <em>Kansas Jack, Inc. v. Kuhn, </em>719 F.2d 1144, 1152, 219 USPQ 857, 862 (Fed. Cir.1983).</p>\n<p id=\"b943-6\">Where a claim, the subject of gross negligence, could not have been allowed due to its cancellation, requiring proof of reliance by actual claim allowance by the PTO would be totally unrealistic. Moreover, an applicant who, with gross negligence, has withheld from the PTO prior art material to a claim in a parent application should not be exculpated simply because, by fortuitous circumstances, the PTO has not reached the stage of allowing claims in a continuing application.</p>\n<p id=\"b943-8\">C\u00e9balo argues that the Belgian and U.S. counterparts of the Canadian patent were among the references included within the scope of the PTO\u2019s search and that there is a presumption that an examiner is aware of all prior art present in the classes and subclasses he searched, citing <em>Richdel, Inc. v. Sunspool Corp., </em>714 F.2d 1573, 1579, 219 USPQ 8, 11 (Fed.Cir.1983). However, in <em>Richdel </em>this court merely held that it was error for the trial court to have required a patentee to prove that prior art had been considered by the PTO in-order to preserve the presumption of validity granted by 35 U.S.C. \u00a7 282, because the statute imposes on his adversary the burden of proving facts necessary to a conclusion of invalidity. <em>Richdel </em>does not speak to the question of whether an examiner\u2019s search of an art class containing a certain reference leads, as a matter of law, to the presumption that the reference was discarded by the examiner as irrelevant. It cannot be presumed, where fraud or other egregious conduct is alleged, that the PTO considered prior art of particular relevance if it was not cited.</p>\n<p id=\"b943-9\">The board\u2019s decision awarding priority to C\u00e9balo in Interference No. 97,757 is <em>reversed and remanded </em>for further proceedings consistent with this opinion. The board\u2019s decision awarding priority to Dris-coll in Interference No. 98,208 is <em>affirmed. </em>Thus, its refusal to consider the fraud issue in Interference 98,208 amounted to harmless abuse of discretion.</p>\n<p id=\"b943-10\">AFFIRMED; REVERSED; AND REMANDED.</p>\n<footnote label=\"1\">\n<p id=\"b937-14\">. The senior party Hoegerle et al. (\"Hoegerle\u201d) filed his application, Serial No. 785,762, December 20, 1968, and was accorded the benefit of Swiss application No. 18,206, filed December 27, 1967, under 35 U.S.C. \u00a7 119 with respect to Count 2. Hoegerle relied solely on his foreign filing date, which was antedated by Cebalo\u2019s reduction to practice on May 12, 1967. Accordingly, as alternatively held by the board, \"[w]ere there fraud on the part of C\u00e9balo, ... priority would be awarded to Driscoll as to Count 1 and to Hoegerle as to Count 2, because C\u00e9balo would not qualify as a party to this interference,\u201d even though Hoegerle has taken no part in this appeal. Hoegerle's assignee is Ciba-Geigy Corp. (\"Ciba\").</p>\n</footnote>\n<footnote label=\"2\">\n<p id=\"aoi-dedup-0\">. <em>Claim 1</em></p>\n<p id=\"a7z-dedup-0\">A compound of the formula</p>\n<blockquote id=\"pAVi\">\n<page-number citation-index=\"1\" label=\"880\">*880</page-number>\n<img class=\"blockquote\" height=\"273\" src=\"data:image/png;base64,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\" width=\"635\"/>\n</blockquote>\n<p id=\"A5S\">wherein</p>\n<p id=\"AApA\">Rl represents a perfluoroalkyl radical of from 1 to 2 carbon atoms,</p>\n<p id=\"a4r-dedup-0\">R2 represents hydrogen or lower alkyl,</p>\n<p id=\"AUFj\">R3 represents hydrogen or lower alkyl, with the proviso that at least one of the symbols R2 and Rg represents hydrogen, and</p>\n<p id=\"ak1-dedup-0\">R4 represents a lower alkyl radical any sub-stituent of which is selected from chlorine, bromine, cyano, lower alkoxy, lower alkyl-thio; alkenyl of from 3 to 4 carbon atoms, alkinyl of from 3 to 4 carbon atoms, cycloal-kyl of from 3 to 6 carbon atoms, and lower alkoxy.</p>\n</footnote>\n<footnote label=\"3\">\n<p id=\"b941-18\">. The party Metzger et al. (\"Metzger\u201d) filed U.S. application Serial No. 230,461 on February 29, 1972, and was accorded the benefit of its Federal Republic of Germany application Serial No. F 53531 filed on September 19, 1967. Metzger relied solely on his foreign filing date under 35 U.S.C. \u00a7 119, but this was antedated by both C\u00e9balo and Driscoll. Metzger takes no part in this appeal.</p>\n</footnote>\n<footnote label=\"4\">\n<p id=\"b942-8\">. \u00a7 1.56 Duty of disclosure; fraud; striking or rejection of applications.</p>\n<p id=\"b942-10\">(d) No patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or gross negligence. The claims in an application shall be rejected if upon examination pursuant to 35 U.S.C. 131 and 132, it is established by clear and convincing evidence (1) that any fraud was practiced or attempted on the Office in connection with the application, or in connection with any previous application upon which the application relies, or (2) that there was any violation of the duty of disclosure through bad faith or gross negligence in connection with the application, <em>or in connection with any previous application upon which the application relies. </em>[Emphasis added.]</p>\n</footnote>\n</opinion>\n</casebody>\n",
    "status": "ok"
  }
}